A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
A phase 1/2 trial of Risvutatug Rezetecan in advanced solid tumours, run by GlaxoSmithKline, now recruiting.
Overview
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) is a phase 1/2 interventional study registered as NCT06885034 by GlaxoSmithKline, with 451 participants planned, started 2025-06-11 and due to reach its primary completion in 2028-01-10. Interventions recorded: Risvutatug Rezetecan, Drug 1, Drug 2, Drug 3 and Drug 4.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Shares GSK and the tag pipeline.
- TrialA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Shares GSK and the tag pipeline.
- TrialFirst-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Shares GSK and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
Shares GSK and the tag pipeline.